APA (7th ed.) Citation

Cohen, E., Licitra, L., Burtness, B., Fayette, J., Gauler, T., Clement, P., . . . Machiels, J. (2016). Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1). International Journal of Radiation Oncology, Biology, Physics, 94(4), 868. https://doi.org/10.1016/j.ijrobp.2015.12.032

Chicago Style (17th ed.) Citation

Cohen, E., et al. "Tumor Biomarker Association With Clinical Outcomes in Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)." International Journal of Radiation Oncology, Biology, Physics 94, no. 4 (2016): 868. https://doi.org/10.1016/j.ijrobp.2015.12.032.

MLA (9th ed.) Citation

Cohen, E., et al. "Tumor Biomarker Association With Clinical Outcomes in Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)." International Journal of Radiation Oncology, Biology, Physics, vol. 94, no. 4, 2016, p. 868, https://doi.org/10.1016/j.ijrobp.2015.12.032.